Most Innovative Companies

Bristol-Myers Squibb

Bristol-Myers Squibb (often stylized as BMS) is an American biotech and pharmaceutical company that creates drugs in many areas like cancer, HIV/AIDS, diabetes, and hepatitis, among others. BMS was born from the 1989 merger of Squibb (founded in 1858 in Brooklyn) and Bristol-Myers (founded in 1887 in Clinton, New York). The 2001 purchase of Delaware-based DuPont Pharmaceuticals solidified the company's already massive portfolio of medicines, creating what was then the world's second-biggest drug maker. An aggressive strategy of targeted acquisitions and partnerships has helped the company maintain one of Big Pharma's most innovative and productive pipelines, with 12 new medicines patented in the past seven years. Top-selling products--including arthritis drug Orencia, HIV treatment Sustiva, and the cancer immunotherapy drug Yervoy--brought in over $4 billion in revenue for the third quarter of 2015, up 4% from 2014. A massive boost in R&D spending--focused in new immunotherapies for cancer--paid off massively in 2015, with a landslide of FDA approvals for a remarkably potent new cancer immunotherapy called Opdivo and the first approval for a combination immunotherapy (Opdivo + Yervoy) for advanced melanoma. First-mover status puts BMS in position to dominate an immuno-oncology market, which is predicted to grow to $30 billion or more in the next five years. Beyond oncology, the company is looking to potential new blockbusters in therapies using its hepatitis-C drug Daklinza, and blood-thinning drug Eliquis.
valuation: $104.62 billion
public or private: Public
profitable: Yes
staff: 25,000+
headquarters: New York, NY
Read More